Evidence map›Paper›PMID 37040826›Full record

ArticleClinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases2023

Which trial do we need? Next-generation sequencing to individualize therapy in Staphylococcus aureus bacteraemia.

Ahmad Mourad, Vance G Fowler, Thomas L Holland

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. The Antibacterial Resistance Leadership Group: Scientific Advancements and Future Directions.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Ahmad MouradDivision of Infectious Diseases, Department of Medicine, Duke University Medical Center, Durham, NC, USA.
Vance G FowlerDivision of Infectious Diseases, Department of Medicine, Duke University Medical Center, Durham, NC, USA.
Thomas L HollandDivision of Infectious Diseases, Department of Medicine, Duke University Medical Center, Durham, NC, USA. Electronic address: thomas.holland@duke.edu.
Duke Medical Center · USDuke University · US

Funding

HLA Fine Mapping to Elucidate S. aureus SusceptibilityR01AI165671 · NIAID · DUKE UNIVERSITY · PI FOWLER, VANCE G., SCOTT, WILLIAM K · 2021 to 2025
$3.8M
NIAID NIH HHS R01 AI165671
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

BacteremiaMethicillin-Resistant Staphylococcus aureusStaphylococcal InfectionsAnti-Bacterial AgentsHigh-Throughput Nucleotide SequencingHumansStaphylococcus aureusAnti-Bacterial Agents

Identifiers

PMID37040826
PMCPMC11105115
OpenAlexW4362736164

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.